Baidu
map

Cancer Res:在前列腺癌中,新的雄激素受体辅助调节因子GRHL2发挥了致瘤作用和抗转移作用

2017-05-15 AlexYang MedSci原创

前列腺癌中,雄激素受体(AR)辅助调节因子的表达和活性的改变是驱动疾病发展和治疗出现抗性的一种重要机制。最近,研究人员利用一种新的蛋白组学技术,鉴定了一个新的AR辅助调节因子-转录因子Grainhead-like 2(GRHL2),并描述了它潜在的在AR信号通路中致瘤角色。研究发现,GRHL2与AR在前列腺肿瘤中共定位,并且在前列腺爱重频繁的扩增和上调。重要的是,GRHL2在多种前列腺癌模型系统中

前列腺癌中,雄激素受体(AR)辅助调节因子的表达和活性的改变是驱动疾病发展和治疗出现抗性的一种重要机制。最近,研究人员利用一种新的蛋白组学技术,鉴定了一个新的AR辅助调节因子-转录因子Grainhead-like 2(GRHL2),并描述了它潜在的在AR信号通路中致瘤角色。

研究发现,GRHL2与AR在前列腺肿瘤中共定位,并且在前列腺爱重频繁的扩增和上调。重要的是,GRHL2在多种前列腺癌模型系统中可维持AR的表达,这种现象对细胞的增殖、改善AR的转录活性是需要的,并且月AR在染色质特异位点的共定位可以调控疾病进展相关的基因。GRHL2自身是一个AR调控基因,这样就在两者之间建立了一个回馈通路。另外,GRHL2与AR的联系同样适用于持续激活的删减了的AR变异体(ARs),即GRHL2可以与ARVs相互作用。GRHL2的这些致瘤功能可以被自身的功能抑制,比如抑制上皮-间质交替和细胞侵入。动力学证据表明了AR可以协助GRHL2维持上皮的表型。最后,研究人员指出,该研究鉴定了一个新的AR辅助调控因子,该调控因子在前列腺癌中具有多面性的角色,可以作为AR致瘤信号通路的增强子,也可以作为转移相关表型的抑制子。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1969252, encodeId=da141969252d6, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 11 14:46:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199229, encodeId=6bc519922946, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed May 17 13:07:55 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350513, encodeId=d783135051336, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 17 12:46:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198729, encodeId=919a198e2929, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 16 10:14:44 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198723, encodeId=41b1198e23a2, content=学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue May 16 09:06:34 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1969252, encodeId=da141969252d6, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 11 14:46:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199229, encodeId=6bc519922946, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed May 17 13:07:55 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350513, encodeId=d783135051336, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 17 12:46:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198729, encodeId=919a198e2929, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 16 10:14:44 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198723, encodeId=41b1198e23a2, content=学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue May 16 09:06:34 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-17 tanxingdoctor

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1969252, encodeId=da141969252d6, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 11 14:46:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199229, encodeId=6bc519922946, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed May 17 13:07:55 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350513, encodeId=d783135051336, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 17 12:46:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198729, encodeId=919a198e2929, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 16 10:14:44 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198723, encodeId=41b1198e23a2, content=学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue May 16 09:06:34 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1969252, encodeId=da141969252d6, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 11 14:46:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199229, encodeId=6bc519922946, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed May 17 13:07:55 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350513, encodeId=d783135051336, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 17 12:46:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198729, encodeId=919a198e2929, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 16 10:14:44 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198723, encodeId=41b1198e23a2, content=学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue May 16 09:06:34 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-16 一个字-牛

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1969252, encodeId=da141969252d6, content=<a href='/topic/show?id=10e09205572' target=_blank style='color:#2F92EE;'>#调节因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92055, encryptionId=10e09205572, topicName=调节因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 11 14:46:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=199229, encodeId=6bc519922946, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Wed May 17 13:07:55 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350513, encodeId=d783135051336, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 17 12:46:00 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198729, encodeId=919a198e2929, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue May 16 10:14:44 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=198723, encodeId=41b1198e23a2, content=学习,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue May 16 09:06:34 CST 2017, time=2017-05-16, status=1, ipAttribution=)]
    2017-05-16 执着追梦

    学习,感谢分享

    0

相关资讯

J Control Release: 在去势难治性前列腺癌中,脂质与寡核苷酸偶联可以提高细胞吞噬和反义-TCTP的效率

翻译控制肿瘤蛋白(TCTP)与细胞生长、细胞周期进程、恶性转化和细胞凋亡的抑制等大量重要细胞学过程相关。因此,TCTP是一个目前被作为一个潜在的治疗几种癌症的靶点,包括前列腺癌、乳腺癌和肺癌。之前,有报道指出,TCTP在去势难治性前列腺癌中(CRPC)是超表达的,并且与治疗的抵抗性有关系。最近,研究人员开发了TCTP反义寡核苷酸链(ASOs)来尝试抑制TCTP的表达。然而,这些ASOs的细胞内传递

Psychooncol: 老年人前列腺癌病人中,抑郁症对雄激素阻断治疗有不良影响

最近,研究人员评估了雄激素阻断治疗(ADT)与抑郁症的关系,并且鉴定了接受ADT的前列腺癌病人中,抑郁症对其的影响。研究人员进行了一个预期的、纵向的且设置对照的研究。研究包括三个老龄病人小组:ADT组(表现出最大雄激素阻断的男性),根治性前列腺切除术组(PR)(前列腺癌对照组:经历根治性前列腺切除术但是没有经历ADT的男性),以及BPH组(前列腺良性增生的男性)。所有的病人完成了人口统计学调查问卷

Oncogenesis:二甲双胍可以抑制SUV39H1调控的前列腺癌细胞迁移

前列腺癌(PCa)是男性癌症相关死亡的主要原因,很大程度上是由于不能治愈的远距离转移。二甲双胍是一种广泛应用于抗糖尿病2型的药物,研究发现,该药能够减少癌症风险并且能取得更好的诊断最近,有研究人员发现,二甲双胍能抑制PCa细胞的迁移,而PCa细胞的迁移与肿瘤转移能力相关。发病机理和肿瘤进展与肿瘤细胞中基因的异常表达相关,主要是通过表观修饰,比如DNA甲基化和组蛋白修饰。研究人员发现,SUV39H

Oncotarget: 脂肪代谢抑制可以使前列腺癌细胞对抗雄激素阻断敏感

前列腺癌(PCa)是西方男性最常见的恶性疾病并且是癌症相关死亡的第二主要原因。对于那些患有转移性激素抵抗性PCa(mCRPC)的病人,存活率是很低的,这也使得对mCRPC新的治疗方法的鉴定变得非常重要。最近,有研究人员发现,通过肉毒碱棕榈酰转移酶诱导的脂肪氧化(CPT1)缺陷可以引起生长和侵入性减弱,强化了脂肪氧化在PCa生长燃料的角色。研究人员利用免疫组化技术发现,与良性组织比较,CPT1A同工

Brit J Cancer:在外周血和前列腺癌风险中,染色体8q24 DNA甲基化的预期研究

染色体8q24表现为几种癌症的重要遗传敏感区域,包括了前列腺癌。然而,该区域的DNA的甲基化对癌症贡献的风险却所知甚少。最近,研究人员预期性的评估了8q24区域DNA甲基化与前列腺癌的关系,实验材料为利用从694名前列腺癌案例(包括172名恶性案例)的诊断前血样和703名在前列腺、肺、大肠和卵巢癌筛选临床实验中的对照,并利用逻辑回归评估让步比和95%置信区间。研究结果发现,在多项检验调整后,50个

Cancer Sci:CLDN8是一个激素调控基因,并且可以促进前列腺癌细胞的增殖和迁移

前列腺癌细胞的增殖是受激素受体(AR)信号途径控制。然而,AR靶基因的功能仍旧还没有很好的阐释。在之前的研究中,研究人员在前列腺癌细胞中鉴定了总体的AR结合位点(ARBS)和AR靶基因。最近,有研究人员关注了封闭蛋白8(CLDN8),且该蛋白能够紧密的结合在细胞膜中。研究发现,在该蛋白核酸序列的启动子区域有一个ARBS,且在序列中有两个功能性的激素响应元件(AREs)。报告基因实验表明了雄激素诱导

Baidu
map
Baidu
map
Baidu
map